8 DAY 1 Thursday, June 20, 2019 Basic Forum 1. Hepatitis Virus (*K) Molecular Basis for Cure of Hepatitis B Virus Infection ··········································································································································· 2 Kyun-Hwan Kim Drug Development for Hepatitis B Virus Treatment ··············································································································································· 5 Sung-Gyoo Park Identification and Validation of Druggable Targets in the Hepatitis C Virus Life Cycle ······························································································ 7 Soon Bong Hwang Hepatitis C Virus Vaccine Development ································································································································································· 8 Eui-Cheol Shin Basic Forum 2. Hepatocellular Carcinoma and Steatohepatitis (*K) Understanding of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma ······································································································ 10 Su-Hyung Park Hepatocarcinogenesis and Animal Model ···························································································································································· 11 Weonsang Ro Hepatic mGluR5 Signaling in Endocannabinoid-Mediated Alcoholic Steatosis ········································································································ 13 Won-il Jeong Pathogenesis of Non-Alcoholic Steatohepatitis ···················································································································································· 15 Sang Geon Kim DAY 2 Friday, June 21, 2019 Symposium 1. Non-Alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease Fecal Microbiota Transplant in Alcoholic Hepatitis ················································································································································ 20 SM Shasthry Systemic Manifestation in Non-Alcoholic Fatty Liver Disease ································································································································· 21 Donghee Kim Update on the Management of Non-Alcoholic Fatty Liver Disease ························································································································ 22 Vincent Wong Special Lectures with Debates: Can We Discontinue Hepatitis B Virus Therapy? Pros. vs. Cons. Nucleoside Analogue (NUC) Treatment Can Be Discontinued ······························································································································· 24 Chun-Jen Liu NUC Treatment Should Be Continued ································································································································································· 25 Young-Suk Lim State-of-the-Art Lecture 1 Hepatitis B Virus: From Control to Cure ······························································································································································ 30 Jia-Horng Kao Symposium 2. Hepatitis B Virus Viral Factors for Hepatitis B Virus-Related Hepatocellular Carcinoma ···················································································································· 32 Jeong Won Jang www.theliverweek.org xix 9 8 Novel Biomarkers in Management of Chronic Hepatitis B ····································································································································· 33 Yasuhito Tanaka Current Treatment Strategy: Towards Hepatitis B Virus Cure ······························································································································· 35 Seng Gee Lim Future Treatment Strategy: Towards Hepatitis B Virus Cure ································································································································· 36 Henry LY Chan Clinical Hepatology Update. Clinical Trials of Management in Chronic Liver Diseases (*K) Chronic Hepatitis B: Where Are We Now for Functional Cure? ···························································································································· 38 Hyun Woong Lee Non-Alcoholic Steatohepatitis: Key Targets and Endpoints ··································································································································· 41 Byoung Kuk Jang Cirrhosis: Effort against Fibrosis and Portal Hypertension ······································································································································ 42 Kyung-Ah Kim Hepatocellular Carcinoma Treatment Showdown: Mono vs. Combination Therapy ······························································································· 46 Ju Hyun Shim Hepatology Associates Course (*K) Treatment of Chronic Hepatitis B and C Virus ····················································································································································· 50 Eileen L. Yoon Management of Acute Variceal Bleeding ···························································································································································· 55 Seung Kak Shin Liver Transplantation: When and How? ······························································································································································ 60 Bum-Soo Kim Hepatocellular Carcinoma: Diagnosis and Tumor Staging ····································································································································· 65 Woo Jin Chung The Liver Week Satellite Symposium for Regeneration Medicine Comparison of Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Normal and Cirrhotic Patients ························································· 72 Young Woo Eom Feasibility of Enhanced PRL-1 in Placenta-derived Mesenchymal Stem Cells by Gene Modification on a Rat Model with Hepatic Failure···················· 74 Gi Jin Kim Vascularized Liver Tissue with Different Types of Endothelial Cells and Recovery Aids for Acute Liver Failure ·························································· 75 Jaeseo Lee, DoYeun Park, Soo Hyun Kim MicroRNA Profile Analysis in Liver Fibrotic Tissue and Hepatic Differentiated Human Bone Marrow-Derived Mesenchymal Stem Cells ····················· 76 Jung Hoon Cha Proteomics Approach for Translational Research, Focusing on Liver Disease ·········································································································· 77 Kyunggon Kim KLTS Symposium 1. Conundrum: Transplanted Liver Pathology Liver Allograft Pathology: Developments in Antibody-Mediated Rejection ············································································································· 80 Christopher Bellamy Is a Protocol Biopsy Needed in a Liver Recipient? ················································································································································· 81 Suk Kyun Hong KAHBPS-KLTS Joint Symposium. Diagnosis and Management of Combined Hepatocellular Carcinoma (HCC) and Cholangiocellular Carcinoma (CCC) Pathological Point of View of Combined HCC and CCA: What Is the Origin and Diagnostic Criteria of Combined HCC and CCA? ························· 84 Young Nyun Park xx June 20-22, 2019 ｜ BEXCO, Busan, South Korea 9 8 Imaging Features of Combined HCC and CCC: What Is the Difference Compared with HCC or CCC? ·································································· 85 Chang-Hee Lee Surgical Treatment and Prognosis of Combined HCC and CCC ···························································································································· 87 Ryusei Matsuyama, Yasuhiro Yabushita, Yuki Homma, Tkafumi Kumamoto, Itaru Endo Issues of Combined HCC and CCC in Liver Transplantation·································································································································· 88 Young Seok Han KLTS Special Lecture Donation after Circulatory Death Liver Procurement in Real Practice ····················································································································· 90 Koji Hashimoto KLTS Symposium 2. Use of Donation after Circulatory Death to Overcome the Decrease of Brain Death Donor (*K) Current Status and Problems of Organ Donation in Korea ··································································································································· 92 Won-Hyun Cho Current Status of Liver Allocation System ···························································································································································· 93 Jae Geun Lee Institutional Issue and Limit of Donation after Cardiac Death ································································································································ 94 Dong-Sik Kim KASL-KLTS Joint Symposium: Hepatorenal Syndrome (HRS) (*K) HRS: Definition, Pathophysiology, and Medical Management ······························································································································· 96 Yeon Seok Seo When to Consider Simultaneous Liver